[{"address1": "Friedrich-Miescher-Strasse 15", "city": "T\u00fcbingen", "zip": "72076", "country": "Germany", "phone": "49 7071 9883 0", "website": "https://www.curevac.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in T\u00fcbingen, Germany.", "fullTimeEmployees": 999, "companyOfficers": [{"maxAge": 1, "name": "Dr. Alexander  Zehnder M.B.A., M.D.", "age": 53, "title": "CEO, MD & Member of Management Board", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1093490, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Pierre  Kemula B.Sc.", "age": 49, "title": "MD, CFO & Member of Management Board", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 731178, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Malte  Greune Ph.D.", "age": 58, "title": "COO, Member of Management Board & MD", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 671449, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Myriam  Mendila M.D.", "age": 57, "title": "Chief Scientific Officer, Head of R&D, MD & Member of the Management Board", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 686817, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ulrike  Gnad-Vogt M.D., Ph.D.", "age": 50, "title": "Senior VP & Area Head of Oncology", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 317592, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sarah  Fakih", "title": "Vice President Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marco  Rau L.L.M., Ph.D.", "title": "General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thorsten  Schuller", "title": "Head of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Slavica  Stevanovic-Heck", "title": "Head of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Patrick  Baumhof", "title": "Senior Vice President of Technology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.81, "open": 2.81, "dayLow": 2.78, "dayHigh": 2.865, "regularMarketPreviousClose": 2.81, "regularMarketOpen": 2.81, "regularMarketDayLow": 2.78, "regularMarketDayHigh": 2.865, "beta": 2.618, "forwardPE": -5.277777, "volume": 688495, "regularMarketVolume": 688495, "averageVolume": 930559, "averageVolume10days": 426910, "averageDailyVolume10Day": 426910, "bid": 2.8, "ask": 2.85, "bidSize": 100, "askSize": 300, "marketCap": 639294848, "fiftyTwoWeekLow": 2.215, "fiftyTwoWeekHigh": 8.93, "priceToSalesTrailing12Months": 9.707024, "fiftyDayAverage": 3.3745, "twoHundredDayAverage": 3.648125, "currency": "USD", "enterpriseValue": 466842368, "floatShares": 123536456, "sharesOutstanding": 224314000, "sharesShort": 5646818, "sharesShortPriorMonth": 7485970, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0252, "heldPercentInsiders": 0.45268002, "heldPercentInstitutions": 0.20183, "shortRatio": 7.58, "shortPercentOfFloat": 0.1409, "bookValue": 1.679, "priceToBook": 1.6974388, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -278430016, "trailingEps": -1.38, "forwardEps": -0.54, "pegRatio": 0.64, "enterpriseToRevenue": 7.089, "enterpriseToEbitda": -1.727, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "CVAC", "underlyingSymbol": "CVAC", "shortName": "CureVac N.V.", "longName": "CureVac N.V.", "firstTradeDateEpochUtc": 1597411800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "340ff847-a470-30d6-90e0-0760c5ece1e8", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.85, "targetHighPrice": 15.95, "targetLowPrice": 2.6, "targetMeanPrice": 7.95, "targetMedianPrice": 6.98, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 202515008, "totalCashPerShare": 0.903, "ebitda": -270342016, "totalDebt": 39035000, "quickRatio": 2.194, "currentRatio": 2.287, "totalRevenue": 65859000, "debtToEquity": 10.367, "revenuePerShare": 0.294, "returnOnAssets": -0.24517, "returnOnEquity": -0.54297, "freeCashflow": -222099008, "operatingCashflow": -289852000, "revenueGrowth": 0.905, "grossMargins": -1.31, "operatingMargins": -4.93579, "financialCurrency": "EUR", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]